Background: Outpatient parenteral antimicrobial therapy (OPAT) is an established approach to patient care. A lack of data on antimicrobial stability within administration devices is a barrier to service expansion, and poses an antimicrobial stewardship dilemma. Often broad-spectrum, long half-life agents are used instead of narrowspectrum agents, which need more frequent administration, but could possibly be used if stability data were available.
Introduction
Outpatient parenteral antimicrobial therapy (OPAT) is an established approach to patient care, the benefits of which are well documented in the literature. [1] [2] [3] [4] [5] [6] [7] Ideally, antimicrobials for OPAT administration should be administered once daily. Once-daily administration can be achieved by either using long half-life antimicrobials or portable administration devices to give an extended or continuous infusion. 8, 9 The use of long half-life agents creates a dilemma for OPAT within the wider stewardship agenda since these agents often have a broad spectrum of activity when compared with alternative antibiotics administered in the inpatient setting. For example, once-daily intravenous ceftriaxone, a broad-spectrum agent, may be used to treat susceptible staphylococcal infection, rather than the evidence-supported narrow-spectrum option of 4-6 hourly, or continuous infusion, intravenous flucloxacillin.
In practice, few OPAT services can support administration of medicines such as flucloxacillin four or more times a day, and there is a lack of accessible and validated antimicrobial stability information to support continuous infusion. In the scenario outlined above many OPAT services accept the risks of using a broad-spectrum agent to gain the benefits of managing the patient in the out-ofhospital setting.
In 2013, BSAC undertook a survey of OPAT practitioners across the UK requesting details on the antimicrobials and administration devices used in their services. A total of 120 OPAT services responded, with 23 stating that they used pre-filled devices for continuous infusion. Of the 23 services using prefilled devices seven responded that they had access to stability data supporting prolongation of the shelf life beyond that stated in the Summary of Product Characteristics. Medicines that these seven services stated they had stability data for were amikacin, aztreonam, ceftazidime, ceftriaxone, colistin, daptomycin, ertapenem, flucloxacillin, gentamicin, meropenem, piperacillin and tazobactam, teicoplanin, tobramycin and vancomycin. More recently, commercial organizations have started to promote devices for antimicrobial infusion. These products may be expensive to non-commercial healthcare organizations and frequently the stability testing data required to support the shelf life are not accessible to scrutiny.
While OPAT is an excellent pathway for managing infections, understanding the stability of antimicrobials in relevant administration devices remains a rate-limiting step in enabling narrowerspectrum agents to be used safely, appropriately and effectively.
In 2014, the British Society of Antimicrobial Chemotherapy UK OPAT Initiative established a work stream to examine published antimicrobial drug stability data.
Within the UK, the Medicines and Healthcare products Regulatory Agency and NHS Standards direct and regulate procedures for compounding medicines into administration devices. The NHS standard includes a minimum dataset required for the assessment of the manufacturer's product stability and shelf-life and is available in the document 'Standard Protocol for Deriving and Assessment of Stability' commonly known as the Yellow-Covered Document (YCD). 10 The aim of this paper was to complete a comprehensive review of published data to document the antimicrobial drug stability literature and assess reports against the minimum dataset standards stated in the YCD.
Methods
This literature review considered drug stability of antimicrobials against the minimum dataset requirements of the YCD. The requirements can be seen in full in the YCD, but include the following.
(i) Testing under relevant storage conditions, e.g. refrigerated or room temperature followed by 'in-use' storage at 37 C for the duration of the infusion.
(ii) At least 95%-105% of active pharmaceutical ingredient (API) to remain to confer stability. Table S1 (available as Supplementary data at JAC Online).
Reference lists of studies reviewed in full text were scanned to identify further studies not found by electronic searching.
Studies were assessed against the YCD minimum dataset by two authors independently and any discrepancies resolved by discussion with other authors. A data extraction form developed by the NHS Pharmaceutical Quality Assurance Committee was used to facilitate the collection of data from each of the reviewed studies.
Results
The literature review was completed in April 2014 and updated in November 2015. A PRISMA flow chart details the numbers of citations identified at each step of the search process ( Figure 1) .
One hundred and twenty-one papers published between 1975 and 2014 were accessed in full text. Descriptors of these papers are found in Table S2 . Of the 121 citations, 72 (60%) were completed in the USA. Studies involving antibacterial agents were most frequent (101 of 121) with antifungal and antiviral reports numbering 11 and 9, respectively.
No papers met minimum dataset requirements of the YCD. The numbers of papers complying with each requirement are outlined in Table 1 .
Discussion
We found no papers reporting antimicrobial drug stability (or instability) that complied with the minimum dataset requirements of the YCD. The most frequent reasons for paper exclusion were unacceptable loss of the API or lack of 'in-use' temperature data.
The British Pharmacopoeia (BP) is unique in containing specifications for finished medicinal products; other pharmacopoeias, for example the US and European versions, have only specifications for raw materials. In general, the BP sets out a shelf-life specification for injectable medicinal products as containing 95%-105% of the stated content; this factor led to the 5% loss limits as a standard in the YCD. 10 The use of a 5% limit for loss of the API, as well as ensuring compliance with the BP, effectively limits the level of uncharacterized degradation compounds in the final product, the consequences of administration of which are frequently unknown. Only 10 of the 121 papers required the API to remain within the tolerance range of 95%-105%. None of these 10 papers has a complete dataset for the remaining elements recommended by the YCD (Table 1) .
The rate at which chemical reactions occur is closely influenced by temperature, with reaction rates increasing with increasing temperature. The YCD requires that all medicines administered via nearpatient devices, e.g. elastomeric devices, are tested at 37 C for the duration of the infusion. In addition, this should be preceded by a period of storage under refrigerated or room temperature conditions as appropriate. Only 10 of the 121 papers undertook stability testing at 37 C. In these 10 papers there are considerable gaps compared with the minimum dataset recommended by the YCD (Table 1) .
Ninety papers tested 'in-use' stability at room temperature (20-25 C), at least 10 C cooler than that recommended in the YCD. 10 As stated previously, the Arrhenius equation would suggest that the rate of degradation at room temperature would be significantly slower than at 37 C. Extrapolation of room temperature data to the clinical environment for near-patient devices, particularly for less stable compounds, may have a significant clinical outcome. Not only may the active drug have degraded to inactive products but these products may also have potential toxicities and unintended consequences for the patient.
Knowledge of the YCD standards outside of the field of Pharmaceutical Quality Assurance is limited. It is imperative, however, that the standards are applied whenever interpreting or assessing stability data for manufacture or procurement of 'readyto-administer' unlicensed (aseptically compounded) products. Only where there are robust data can compounded products with extended shelf lives be safely used to provide an OPAT service. It is important that service providers understand the need for stability studies to comply with the YCD.
This review has demonstrated that there are no data in the published literature compliant with the YCD minimum dataset to support extended shelf-life stability of antimicrobials.
Healthcare professionals working outside the highly specialist fields of quality assurance may not be aware of the requirements of the NHS standards outlined in the YCD. Ensuring compliance of published or unpublished stability data with these minimum standards is a fundamental part of assuring the reliability and clinical governance of the OPAT service as a whole.
Conclusions
OPAT is an established healthcare option with well documented advantages for patients and the healthcare economy.
To support service expansion within the remit of the stewardship agenda, access to stability data of narrow-spectrum antimicrobials in appropriate administration devices is essential.
Following a comprehensive search, this review found no published stability studies that comply with a UK minimum dataset for shelf-life extension outlined in the YCD. Extended stability of antimicrobial agents in administration devices JAC A lack of published YCD-compliant stability studies is hampering OPAT expansion within the stewardship agenda since services are compelled to use broad-spectrum, once-daily agents.
We recommend further research and publication of new and any previous work to support the OPAT community in this area.
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